243 related articles for article (PubMed ID: 36672491)
1. Therapeutic Management of Adults with Inflammatory Bowel Disease and Malignancies: A Clinical Challenge.
Ferretti F; Cannatelli R; Maconi G; Ardizzone S
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672491
[TBL] [Abstract][Full Text] [Related]
2. Extraintestinal Cancers in Inflammatory Bowel Disease: A Literature Review.
Massano A; Bertin L; Zingone F; Buda A; Visaggi P; Bertani L; de Bortoli N; Fassan M; Scarpa M; Ruffolo C; Angriman I; Bezzio C; Casini V; Ribaldone DG; Savarino EV; Barberio B
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568640
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
[TBL] [Abstract][Full Text] [Related]
4. Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB).
Romero RK; Magro DO; Queiroz NSF; Damião AOMC; Teixeira FV; Nones RB; Sassaki LY; Saad-Hossne R; Kotze PG
Gastroenterol Hepatol; 2022; 45(7):499-506. PubMed ID: 34634427
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy in inflammatory bowel disease: Current evidence and perspectives.
Dai C; Huang YH; Jiang M
Int Immunopharmacol; 2023 Jan; 114():109545. PubMed ID: 36508920
[TBL] [Abstract][Full Text] [Related]
6. The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer.
Wetwittayakhlang P; Tselekouni P; Al-Jabri R; Bessissow T; Lakatos PL
J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983432
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment.
Hyun HK; Zhang HS; Yu J; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
BMC Gastroenterol; 2022 Mar; 22(1):143. PubMed ID: 35346063
[TBL] [Abstract][Full Text] [Related]
8. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
9. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
Barré A; Colombel JF; Ungaro R
Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
[TBL] [Abstract][Full Text] [Related]
10. Ustekinumab does not increase risk of new or recurrent cancer in inflammatory bowel disease patients with prior malignancy.
Hasan B; Tandon KS; Miret R; Khan S; Riaz A; Gonzalez A; Rahman AU; Charles R; Narula N; Castro FJ
J Gastroenterol Hepatol; 2022 Jun; 37(6):1016-1021. PubMed ID: 35191100
[TBL] [Abstract][Full Text] [Related]
11. Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease?
Gilroy L; Allen PB
Clin Exp Gastroenterol; 2014; 7():163-72. PubMed ID: 24899819
[TBL] [Abstract][Full Text] [Related]
12. Management of Inflammatory Bowel Disease in Patients with Current or Past Malignancy.
Poullenot F; Laharie D
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831424
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease.
Goll R; Moe ØK; Johnsen KM; Meyer R; Friestad J; Gundersen MD; Kileng H; Johnsen K; Florholmen JR
BMC Gastroenterol; 2022 Nov; 22(1):464. PubMed ID: 36384462
[TBL] [Abstract][Full Text] [Related]
14. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
15. 5-Aminosalicylic Acid Chemoprevention in Inflammatory Bowel Diseases: Is It Necessary in the Age of Biologics and Small Molecules?
Herfarth H; Vavricka SR
Inflamm Intest Dis; 2022 Jan; 7(1):28-35. PubMed ID: 35224015
[TBL] [Abstract][Full Text] [Related]
16. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
17. Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease.
Dolinger MT; Spencer EA; Lai J; Dunkin D; Dubinsky MC
Inflamm Bowel Dis; 2021 Jul; 27(8):1210-1214. PubMed ID: 33125058
[TBL] [Abstract][Full Text] [Related]
18. Dual biological therapy and small molecules in pediatric inflammatory bowel disease.
Penagini F; Lonoce L; Abbattista L; Silvera V; Rendo G; Cococcioni L; Dilillo D; Calcaterra V; Zuccotti GV
Pharmacol Res; 2023 Oct; 196():106935. PubMed ID: 37748559
[TBL] [Abstract][Full Text] [Related]
19. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
[TBL] [Abstract][Full Text] [Related]
20. Therapy in elderly IBD patients.
Castiglione F; Imperatore N; Zingone F; D'Incà R
Minerva Gastroenterol (Torino); 2024 Mar; 70(1):89-97. PubMed ID: 34160188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
